{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,3]],"date-time":"2026-03-03T03:15:43Z","timestamp":1772507743510,"version":"3.50.1"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,7,20]],"date-time":"2022-07-20T00:00:00Z","timestamp":1658275200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"Medical Research Council","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010269","name":"Wellcome Trust","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010269","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["FC001060"],"award-info":[{"award-number":["FC001060"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010438","name":"Francis Crick Institute","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010438","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004330","name":"GlaxoSmithKline","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004330","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100014013","name":"UK Research and Innovation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014013","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmn.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Current Opinion in Microbiology"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.mib.2022.102191","type":"journal-article","created":{"date-parts":[[2022,8,12]],"date-time":"2022-08-12T19:22:56Z","timestamp":1660332176000},"page":"102191","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Bottlenecks and opportunities in antibiotic discovery against Mycobacterium tuberculosis"],"prefix":"10.1016","volume":"69","author":[{"given":"Peter D","family":"Craggs","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Luiz Pedro S","family":"de Carvalho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.mib.2022.102191_bib1","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00655-2019","article-title":"The global prevalence of latent tuberculosis: a systematic review and meta-analysis","volume":"54","author":"Cohen","year":"2019","journal-title":"Eur Respir J"},{"key":"10.1016\/j.mib.2022.102191_bib2","doi-asserted-by":"crossref","first-page":"905","DOI":"10.1007\/s00228-016-2083-4","article-title":"Optimizing treatment outcome of first-line anti-tuberculosis drugs: the role of therapeutic drug monitoring","volume":"72","author":"Verbeeck","year":"2016","journal-title":"Eur J Clin Pharm"},{"key":"10.1016\/j.mib.2022.102191_bib3","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.03300-2020","article-title":"World Health Organization recommendations on the treatment of drug-resistant tuberculosis, 2020 update","volume":"57","author":"Mirzayev","year":"2021","journal-title":"Eur Respir J"},{"key":"10.1016\/j.mib.2022.102191_bib4","doi-asserted-by":"crossref","first-page":"893","DOI":"10.1056\/NEJMoa1901814","article-title":"Treatment of Highly Drug-Resistant Pulmonary Tuberculosis","volume":"382","author":"Conradie","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.mib.2022.102191_bib5","doi-asserted-by":"crossref","first-page":"S96","DOI":"10.1016\/j.ijid.2021.02.067","article-title":"Accelerating development of new shorter TB treatment regimens in anticipation of a resurgence of multi-drug resistant TB due to the COVID-19 pandemic","volume":"113 Suppl 1","author":"Tiberi","year":"2021","journal-title":"Int J Infect Dis"},{"key":"10.1016\/j.mib.2022.102191_bib6","doi-asserted-by":"crossref","DOI":"10.1038\/s41579-022-00731-y","article-title":"Anti-tuberculosis treatment strategies and drug development: challenges and priorities","author":"Dartois","year":"2022","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.mib.2022.102191_bib7","doi-asserted-by":"crossref","DOI":"10.1093\/cid\/ciac019","article-title":"Safety of treatment regimens containing bedaquiline and delamanid in the endTB cohort","author":"Hewison","year":"2022","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.mib.2022.102191_bib8","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.jgar.2018.09.006","article-title":"Whole-genome sequencing reveals genetic signature of bedaquiline resistance in a clinical isolate of Mycobacterium tuberculosis","volume":"15","author":"Chawla","year":"2018","journal-title":"J Glob Antimicrob Resist"},{"key":"10.1016\/j.mib.2022.102191_bib9","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/jac\/dkz206","article-title":"Linezolid resistance in patients with drug-resistant TB and treatment failure in South Africa","volume":"74","author":"Wasserman","year":"2019","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.mib.2022.102191_bib10","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1093\/femsre\/fux011","article-title":"Antimicrobial resistance in Mycobacterium tuberculosis: mechanistic and evolutionary perspectives","volume":"41","author":"Gygli","year":"2017","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/j.mib.2022.102191_bib11","doi-asserted-by":"crossref","DOI":"10.1093\/femsre\/fuab050","article-title":"Critical discussion on drug efflux in Mycobacterium tuberculosis","volume":"46","author":"Remm","year":"2022","journal-title":"FEMS Microbiol Rev"},{"key":"10.1016\/j.mib.2022.102191_bib12","doi-asserted-by":"crossref","first-page":"550","DOI":"10.3390\/antibiotics9090550","article-title":"Novel treatments against Mycobacterium tuberculosis based on drug repurposing","volume":"9","author":"Mourenza","year":"2020","journal-title":"Antibiotics"},{"key":"10.1016\/j.mib.2022.102191_bib13","doi-asserted-by":"crossref","first-page":"5633","DOI":"10.1007\/s00253-020-10606-y","article-title":"Potential anti-TB investigational compounds and drugs with repurposing potential in TB therapy: a conspectus","volume":"104","author":"Adeniji","year":"2020","journal-title":"Appl Microbiol Biotechnol"},{"key":"10.1016\/j.mib.2022.102191_bib14","doi-asserted-by":"crossref","first-page":"11998","DOI":"10.1021\/bi701506h","article-title":"Irreversible inhibition of the Mycobacterium tuberculosis beta-lactamase by clavulanate","volume":"46","author":"Hugonnet","year":"2007","journal-title":"Biochemistry"},{"key":"10.1016\/j.mib.2022.102191_bib15","doi-asserted-by":"crossref","first-page":"5312","DOI":"10.1021\/bi8001055","article-title":"Structure of the covalent adduct formed between Mycobacterium tuberculosis beta-lactamase and clavulanate","volume":"47","author":"Tremblay","year":"2008","journal-title":"Biochemistry"},{"key":"10.1016\/j.mib.2022.102191_bib16","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1126\/science.1167498","article-title":"Meropenem-clavulanate is effective against extensively drug-resistant Mycobacterium tuberculosis","volume":"323","author":"Hugonnet","year":"2009","journal-title":"Science"},{"key":"10.1016\/j.mib.2022.102191_sbref17","doi-asserted-by":"crossref","first-page":"2425","DOI":"10.1021\/acsinfecdis.1c00185","article-title":"Atypically modified carbapenem antibiotics display improved antimycobacterial activity in the absence of beta-Lactamase inhibitors","volume":"7","author":"Gupta","year":"2021","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.mib.2022.102191_bib18","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1186\/s12866-020-01954-w","article-title":"Ertapenem and Faropenem against Mycobacterium tuberculosis: in vitro testing and comparison by macro and microdilution","volume":"20","author":"Gonzalo","year":"2020","journal-title":"BMC Microbiol"},{"key":"10.1016\/j.mib.2022.102191_bib19","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1016\/j.chembiol.2021.03.008","article-title":"N-Thio-beta-lactams targeting L,D-transpeptidase-2, with activity against drug-resistant strains of Mycobacterium tuberculosis","volume":"28","author":"Martelli","year":"2021","journal-title":"Cell Chem Biol"},{"key":"10.1016\/j.mib.2022.102191_bib20","doi-asserted-by":"crossref","first-page":"3861","DOI":"10.1128\/AAC.00474-11","article-title":"Synergistic drug combinations for tuberculosis therapy identified by a novel high-throughput screen","volume":"55","author":"Ramon-Garcia","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mib.2022.102191_bib21","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1038\/nm.3458","article-title":"Spectinamides: a new class of semisynthetic antituberculosis agents that overcome native drug efflux","volume":"20","author":"Lee","year":"2014","journal-title":"Nat Med"},{"key":"10.1016\/j.mib.2022.102191_sbref22","doi-asserted-by":"crossref","first-page":"2850","DOI":"10.1021\/acsinfecdis.1c00213","article-title":"Preclinical evaluation of inhalational spectinamide-1599 therapy against tuberculosis","volume":"7","author":"Gonzalez-Juarrero","year":"2021","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.mib.2022.102191_bib23","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.01744-20","article-title":"Model-based exposure-response assessment for spectinamide 1810 in a mouse model of tuberculosis","volume":"65","author":"Wagh","year":"2021","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.mib.2022.102191_bib24","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1021\/acsinfecdis.6b00158","article-title":"Structure-activity relationships of spectinamide antituberculosis agents: a dissection of ribosomal inhibition and native efflux avoidance contributions","volume":"3","author":"Liu","year":"2017","journal-title":"ACS Infect Dis"},{"key":"10.1016\/j.mib.2022.102191_sbref25","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-019-12074-z","article-title":"Comparative fitness analysis of D-cycloserine resistant mutants reveals both fitness-neutral and high-fitness cost genotypes","volume":"10","author":"Evangelopoulos","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.mib.2022.102191_bib26","doi-asserted-by":"crossref","first-page":"7145","DOI":"10.1021\/bi400839f","article-title":"Reinterpreting the mechanism of inhibition of Mycobacterium tuberculosis D-alanine:D-alanine ligase by D-cycloserine","volume":"52","author":"Prosser","year":"2013","journal-title":"Biochemistry"},{"key":"10.1016\/j.mib.2022.102191_bib27","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-017-02118-7","article-title":"Inhibition of D-Ala:D-Ala ligase through a phosphorylated form of the antibiotic D-cycloserine","volume":"8","author":"Batson","year":"2017","journal-title":"Nat Commun"},{"key":"10.1016\/j.mib.2022.102191_sbref28","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1038\/s41589-020-0498-9","article-title":"D-Cycloserine destruction by alanine racemase and the limit of irreversible inhibition","volume":"16","author":"de Chiara","year":"2020","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.mib.2022.102191_bib29","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2008610118","article-title":"Competing off-loading mechanisms of meropenem from an l,d-transpeptidase reduce antibiotic effectiveness","volume":"118","author":"Zandi","year":"2021","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.mib.2022.102191_bib30","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1038\/s41579-018-0013-4","article-title":"Metabolic principles of persistence and pathogenicity in Mycobacterium tuberculosis","volume":"16","author":"Ehrt","year":"2018","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.mib.2022.102191_bib31","doi-asserted-by":"crossref","first-page":"S25","DOI":"10.1016\/S1472-9792(08)70034-9","article-title":"A philosophy of anti-infectives as a guide in the search for new drugs for tuberculosis","volume":"88 Suppl 1","author":"Nathan","year":"2008","journal-title":"Tuberculosis"},{"key":"10.1016\/j.mib.2022.102191_bib32","doi-asserted-by":"crossref","DOI":"10.1128\/microbiolspec.GPP3-0067-2019","article-title":"Mycobacterium tuberculosis metabolism","volume":"7","author":"Mashabela","year":"2019","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.mib.2022.102191_sbref33","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1021\/acs.accounts.9b00275","article-title":"Harnessing biological insight to accelerate tuberculosis drug discovery","volume":"52","author":"de Wet","year":"2019","journal-title":"Acc Chem Res"},{"key":"10.1016\/j.mib.2022.102191_bib34","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.41129","article-title":"Flexible nitrogen utilisation by the metabolic generalist pathogen Mycobacterium tuberculosis","volume":"8","author":"Agapova","year":"2019","journal-title":"Elife"},{"key":"10.1016\/j.mib.2022.102191_bib35","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1016\/j.chembiol.2010.08.009","article-title":"Metabolomics of Mycobacterium tuberculosis reveals compartmentalized co-catabolism of carbon substrates","volume":"17","author":"de Carvalho","year":"2010","journal-title":"Chem Biol"},{"key":"10.1016\/j.mib.2022.102191_bib36","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1111\/mmi.14362","article-title":"Mycobacterium tuberculosis requires glyoxylate shunt and reverse methylcitrate cycle for lactate and pyruvate metabolism","volume":"112","author":"Serafini","year":"2019","journal-title":"Mol Microbiol"},{"key":"10.1016\/j.mib.2022.102191_bib37","doi-asserted-by":"crossref","first-page":"4376","DOI":"10.1073\/pnas.0711159105","article-title":"Mycobacterial persistence requires the utilization of host cholesterol","volume":"105","author":"Pandey","year":"2008","journal-title":"Proc Natl Acad Sci USA"},{"key":"10.1016\/j.mib.2022.102191_bib38","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.43621","article-title":"The genetic requirements of fatty acid import by Mycobacterium tuberculosis within macrophages","volume":"8","author":"Nazarova","year":"2019","journal-title":"Elife"},{"key":"10.1016\/j.mib.2022.102191_bib39","doi-asserted-by":"crossref","DOI":"10.1038\/s41467-021-26941-1","article-title":"Multiple acyl-CoA dehydrogenase deficiency kills Mycobacterium tuberculosis in vitro and during infection","volume":"12","author":"Beites","year":"2021","journal-title":"Nat Commun"},{"key":"10.1016\/j.mib.2022.102191_bib40","doi-asserted-by":"crossref","first-page":"7912","DOI":"10.1038\/ncomms8912","article-title":"Two enzymes with redundant fructose bisphosphatase activity sustain gluconeogenesis and virulence in Mycobacterium tuberculosis","volume":"6","author":"Ganapathy","year":"2015","journal-title":"Nat Commun"},{"key":"10.1016\/j.mib.2022.102191_bib41","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/nchembio.1355","article-title":"Mycobacterium tuberculosis nitrogen assimilation and host colonization require aspartate","volume":"9","author":"Gouzy","year":"2013","journal-title":"Nat Chem Biol"},{"key":"10.1016\/j.mib.2022.102191_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003928","article-title":"Mycobacterium tuberculosis exploits asparagine to assimilate nitrogen and resist acid stress during infection","volume":"10","author":"Gouzy","year":"2014","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.mib.2022.102191_bib43","doi-asserted-by":"crossref","first-page":"1879","DOI":"10.1021\/acschembio.9b00204","article-title":"Structural basis of glycerophosphodiester recognition by the Mycobacterium tuberculosis substrate-binding protein UgpB","volume":"14","author":"Fenn","year":"2019","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.mib.2022.102191_bib44","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1009862","article-title":"Pharmacological and genetic activation of cAMP synthesis disrupts cholesterol utilization in Mycobacterium tuberculosis","volume":"18","author":"Wilburn","year":"2022","journal-title":"PLoS Pathog"},{"key":"10.1016\/j.mib.2022.102191_bib45","doi-asserted-by":"crossref","DOI":"10.1038\/ncomms1060","article-title":"A chemical genetic screen in Mycobacterium tuberculosis identifies carbon-source-dependent growth inhibitors devoid of in vivo efficacy","volume":"1","author":"Pethe","year":"2010","journal-title":"Nat Commun"},{"key":"10.1016\/j.mib.2022.102191_bib46","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1038\/nrd2201","article-title":"Drugs for bad bugs: confronting the challenges of antibacterial discovery","volume":"6","author":"Payne","year":"2007","journal-title":"Nat Rev Drug Disco"},{"key":"10.1016\/j.mib.2022.102191_bib47","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1099\/mic.0.2007\/012872-0","article-title":"Nutrient acquisition by mycobacteria","volume":"154","author":"Niederweis","year":"2008","journal-title":"Microbiology"},{"key":"10.1016\/j.mib.2022.102191_bib48","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.mib.2021.01.012","article-title":"Synthesis and recycling of the mycobacterial cell envelope","volume":"60","author":"Abrahams","year":"2021","journal-title":"Curr Opin Microbiol"},{"key":"10.1016\/j.mib.2022.102191_bib49","doi-asserted-by":"crossref","first-page":"313","DOI":"10.1002\/cmdc.201200428","article-title":"Fueling open-source drug discovery: 177 small-molecule leads against tuberculosis","volume":"8","author":"Ballell","year":"2013","journal-title":"ChemMedChem"},{"key":"10.1016\/j.mib.2022.102191_bib50","doi-asserted-by":"crossref","DOI":"10.3389\/fcimb.2021.611304","article-title":"Tuberculosis drug discovery: a decade of hit assessment for defined targets","volume":"11","author":"Oh","year":"2021","journal-title":"Front Cell Infect Microbiol"},{"key":"10.1016\/j.mib.2022.102191_sbref51","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1038\/s41586-019-1315-z","article-title":"Large-scale chemical-genetics yields new M. tuberculosis inhibitor classes","volume":"571","author":"Johnson","year":"2019","journal-title":"Nature"},{"key":"10.1016\/j.mib.2022.102191_bib52","doi-asserted-by":"crossref","first-page":"158","DOI":"10.1002\/emmm.201201772","article-title":"Tuberculosis drug discovery in the post-post-genomic era","volume":"6","author":"Lechartier","year":"2014","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.mib.2022.102191_bib53","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.coph.2018.06.006","article-title":"Therapeutic potential of promiscuous targets in Mycobacterium tuberculosis","volume":"42","author":"Lee","year":"2018","journal-title":"Curr Opin Pharm"},{"key":"10.1016\/j.mib.2022.102191_bib54","doi-asserted-by":"crossref","first-page":"9792","DOI":"10.1021\/acs.jmedchem.9b01199","article-title":"Structure-activity relationships of cyclo(l-Tyrosyl-l-tyrosine) derivatives binding to Mycobacterium tuberculosis CYP121: iodinated analogues promote shift to high-spin adduct","volume":"62","author":"Rajput","year":"2019","journal-title":"J Med Chem"},{"key":"10.1016\/j.mib.2022.102191_bib55","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1021\/acs.jmedchem.6b00007","article-title":"Fragment-based approaches to the development of Mycobacterium tuberculosis CYP121 inhibitors","volume":"59","author":"Kavanagh","year":"2016","journal-title":"J Med Chem"},{"key":"10.1016\/j.mib.2022.102191_bib56","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1021\/acsmedchemlett.7b00239","article-title":"Mtb PKNA\/PKNB dual inhibition provides selectivity advantages for inhibitor design to minimize host kinase interactions","volume":"8","author":"Wang","year":"2017","journal-title":"ACS Med Chem Lett"},{"key":"10.1016\/j.mib.2022.102191_bib57","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1128\/microbiolspec.MGM2-0006-2013","article-title":"Mycobacterium tuberculosis serine\/threonine protein kinases","volume":"2","author":"Prisic","year":"2014","journal-title":"Microbiol Spectr"},{"key":"10.1016\/j.mib.2022.102191_sbref58","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/nature22308","article-title":"Predictive compound accumulation rules yield a broad-spectrum antibiotic","volume":"545","author":"Richter","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.mib.2022.102191_bib59","doi-asserted-by":"crossref","first-page":"10856","DOI":"10.1021\/jacs.0c04427","article-title":"Gram-negative antibiotic active through inhibition of an essential Riboswitch","volume":"142","author":"Motika","year":"2020","journal-title":"J Am Chem Soc"},{"key":"10.1016\/j.mib.2022.102191_bib60","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(00)00129-0","article-title":"Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings","volume":"46","author":"Lipinski","year":"2001","journal-title":"Adv Drug Deliv Rev"},{"key":"10.1016\/j.mib.2022.102191_bib61","doi-asserted-by":"crossref","first-page":"1797","DOI":"10.1007\/s40265-019-01207-9","article-title":"Pretomanid: first approval","volume":"79","author":"Keam","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.mib.2022.102191_bib62","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1093\/biostatistics\/kxx069","article-title":"Estimation of clinical trial success rates and related parameters","volume":"20","author":"Wong","year":"2019","journal-title":"Biostatistics"},{"key":"10.1016\/j.mib.2022.102191_bib63","doi-asserted-by":"crossref","first-page":"2031","DOI":"10.1093\/jac\/dkaa136","article-title":"Systematic review of mutations associated with resistance to the new and repurposed Mycobacterium tuberculosis drugs bedaquiline, clofazimine, linezolid, delamanid and pretomanid","volume":"75","author":"Kadura","year":"2020","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.mib.2022.102191_bib64","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/s41564-022-01130-y","article-title":"CRISPRi chemical genetics and comparative genomics identify genes mediating drug potency in Mycobacterium tuberculosis","volume":"7","author":"Li","year":"2022","journal-title":"Nat Microbiol"},{"key":"10.1016\/j.mib.2022.102191_bib65","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1016\/j.coph.2018.08.001","article-title":"The present state of the tuberculosis drug development pipeline","volume":"42","author":"MD","year":"2018","journal-title":"Curr Opin Pharm"}],"container-title":["Current Opinion in Microbiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1369527422000753?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1369527422000753?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,24]],"date-time":"2025-10-24T05:54:49Z","timestamp":1761285289000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1369527422000753"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":65,"alternative-id":["S1369527422000753"],"URL":"https:\/\/doi.org\/10.1016\/j.mib.2022.102191","relation":{},"ISSN":["1369-5274"],"issn-type":[{"value":"1369-5274","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Bottlenecks and opportunities in antibiotic discovery against Mycobacterium tuberculosis","name":"articletitle","label":"Article Title"},{"value":"Current Opinion in Microbiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.mib.2022.102191","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Author(s). Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"102191"}}